Company intelligence / Profile preview

Suzhou Ribo Life Science

Kunshan, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

Suzhou Ribo Life Science has multiple siRNA drug candidates in Phase 2 and Phase 3 clinical trials targeting cardiovascular, metabolic, renal, and liver diseases. Their lead programs have shown successful patient enrollment and international trial approvals, with several drugs advancing through global multi-center studies and collaborations with multinational pharma companies.[1][4][8]

Therapeutic areas: NephrologyMetabolic DisordersOphthalmologyInfectious DiseasesGastroenterologyCardiovascular
Modalities: Small interfering RNAOligonucleotidemRNA-based drugs
Industry: Biotech

Partnerships

Boehringer IngelheimQilu Pharmaceutical

Beyond the preview

Go deeper on Suzhou Ribo Life Science.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Suzhou Ribo Life Science.

Explore the full profile